Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually.

Chronic diseases require a lifetime of long-term follow-up. Randomised controlled trials are considered the most robust ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...